Also trades as: CEROW (OTC) · $vol 0M
CERO OTC
CERo Therapeutics Holdings, Inc.
1W: -25.9%
1M: -38.0%
3M: -50.0%
YTD: -70.2%
1Y: -99.8%
3Y: -100.0%
$0.02
+0.00 (+2.50%)
Weekly Expected Move ±30.0%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.0M
52W Range0.018-26.99
Volume0
Avg Volume514,032
Beta0.24
Dividend—
Analyst Ratings
Company Info
CEOChristopher Ehrlich
Employees8
SectorHealthcare
IndustryBiotechnology
IPO Date2021-11-30
Websitecero.bio
201 Haskins Way
South San Francisco, CA 94080
US
South San Francisco, CA 94080
US
(650) 407-2376
About CERo Therapeutics Holdings, Inc.
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
Latest News
CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial
CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial
Small-Cap healthcare stocks ranked by quant ratings after earnings season
CERo Therapeutics Provides Shareholder Update
CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Francois Eric | A-Award | 1,823,278 | $0.06 | 2026-03-04 |
| Francois Eric | 0 | — | 2026-02-13 | |
| Rolfe Lindsey | A-Award | 690,900 | $0.06 | 2026-01-07 |
| LAPORTE KATHLEEN | A-Award | 690,900 | $0.06 | 2026-01-07 |
| Patel Shami | A-Award | 690,900 | $0.06 | 2026-01-07 |